46 results on '"Ragan, Ian"'
Search Results
2. An evaluation of the fixed concentration procedure for assessment of acute inhalation toxicity
3. New supporting data to guide the use of evident toxicity in acute oral toxicity studies (OECD TG 420)
4. Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop
5. Applying the 3Rs to non-human primate research: Barriers and solutions
6. Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)
7. Opportunities for improving animal welfare in rodent models of epilepsy and seizures
8. The Current Status and Work of Three Rs Centres and Platforms in Europe*
9. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials
10. Advancing the 3Rs in regulatory toxicology – Carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union
11. Steps towards the international regulatory acceptance of non-animal methodology in safety assessment
12. The Rise of Three Rs Centres and Platforms in Europe*
13. The Current Status and Work of Three Rs Centres and Platforms in Europe*
14. The Rise of Three Rs Centres and Platforms in Europe*
15. Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals
16. The future of non-human primate use in mAb development
17. Preclinical screening for antidepressant activity – shifting focus away from the Forced Swim Test to the use of translational biomarkers
18. A global initiative to refine acute inhalation studies through the use of ‘evident toxicity’ as an endpoint: Towards adoption of the fixed concentration procedure
19. LAB ANIMALS: Can GM marmoset use be justified?
20. Consensus document on European brain research
21. TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates
22. What should we do about student use of cognitive enhancers? An analysis of current evidence
23. Consensus Document on European Brain Research
24. Drugs Futures 2025? Perspective of the Pharmaceutical Industry
25. Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates
26. Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina
27. Apolipoprotein E genotyping in Alzheimer's disease
28. The autism dividend. Reaping the rewards of better investment
29. The National Autism Project (NAP) Legacy Forum 2018: what's happened since the publication of the NAP report in 2017?
30. Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop
31. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges
32. Alcohol alternatives--a goal for psychopharmacology?
33. Chapter 18 - Drugs Futures 2025? Perspective of the Pharmaceutical Industry
34. Preclinical safety testing of monoclonal antibodies: the significance of species relevance
35. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4- triazol-3-ylmethoxy)-3-(2-fluorophenyl)- 1,2,4-triazolo[4,3-b]pyridazine: A Functionally Selective γ-Aminobutyric AcidA (GABAA) α2/α3-Subtype Selective Agonist That Exhibits Potent Anxiolytic Activity but Is Not Sedating in Animal Models
36. TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAAReceptors, Is a Nonsedating Anxiolytic in Rodents and Primates
37. Alcohol alternatives – a goal for psychopharmacology?
38. 3-(1-Piperazinyl)-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D4 receptor with improved selectivity over ion channels
39. Apolipoprotein E genotyping in Alzheimer's disease
40. Determination of the cDNA sequence for the human mitochondrial 75‐kDa Fe–S protein of NADH‐coenzyme Q reductase
41. TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAAReceptors, Is a Nonsedating Anxiolytic in Rodents and Primates
42. TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for {alpha}2- and {alpha}3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates.
43. Curbing our animal instinct: How 3R technology is aiming at superiority.
44. 3-(1-Piperazinyl)-4,5-dihydro-1H-benzo[g]indazoles: high affinity ligands for the human dopamine D 4 receptor with improved selectivity over ion channels
45. Studies on reconstituted quinol oxidase
46. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.